Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients
Status:
Active, not recruiting
Trial end date:
2022-09-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess pain management after elective thoracoscopic
lobectomy. The study will compare two local anesthetics that are given intra-operatively
during lobectomy to see which one helps in better pain control and to see which one helps
decrease the need for opioid medications. Participants will receive either Marcaine
(Bupivacaine-epinephrine 0.25%, 1:200,000) or Exparel (Bupivacaine liposomal (1.3%)) and the
drug will be chosen in a random fashion. Participants will be followed during the hospital
stay and for one year thereafter. An visual Scale will be administered to measure pain, and
opioid drug use will be measured by calculating morphine equivalent dose on each day post
surgery until discharge and thereafter on 30 day, 6 month and 12 month follow-up visits.
Participants will be monitored for any drug related toxicity and other co-morbid conditions
for a period on one year post surgery. Overall cost for the surgery and during in hospital
stay post surgery will be collected and compared between the two treatment arms.